V
The startup develops regenerative cell therapies for retinal degeneration diseases by producing retinal pigment epithelial cells and photoreceptor cells from allogeneic induced pluripotent stem (iPS) cells. Utilizing automated manufacturing technology and artificial intelligence analytics, the company enhances treatment options for healthcare professionals, improving patient outcomes.
Kobe, Japan
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops regenerative cell therapies for retinal degeneration diseases by producing retinal pigment epithelial cells and photoreceptor cells from allogeneic induced pluripotent stem (iPS) cells. Utilizing automated manufacturing technology and artificial intelligence analytics, the company enhances treatment options for healthcare professionals, improving patient outcomes.